MX2015007436A - Forma de dosificacion oral solida de derivado de testosterona. - Google Patents

Forma de dosificacion oral solida de derivado de testosterona.

Info

Publication number
MX2015007436A
MX2015007436A MX2015007436A MX2015007436A MX2015007436A MX 2015007436 A MX2015007436 A MX 2015007436A MX 2015007436 A MX2015007436 A MX 2015007436A MX 2015007436 A MX2015007436 A MX 2015007436A MX 2015007436 A MX2015007436 A MX 2015007436A
Authority
MX
Mexico
Prior art keywords
dosage form
oral dosage
solid oral
testosterone derivative
fat component
Prior art date
Application number
MX2015007436A
Other languages
English (en)
Other versions
MX360186B (es
Inventor
Bent Højgaard
Original Assignee
Solural Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solural Pharma ApS filed Critical Solural Pharma ApS
Publication of MX2015007436A publication Critical patent/MX2015007436A/es
Publication of MX360186B publication Critical patent/MX360186B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un derivado de testosterona que tiene un log p de al menos 5 y un vehículo, en donde el vehículo comprende un componente graso en una cantidad suficiente para lograr la absorción linfática en un mamífero, en donde el componente graso comprende un mono o triglicérido de ácidos grasos de cadena larga.
MX2015007436A 2012-12-20 2013-12-19 Forma de dosificacion oral solida de derivado de testosterona. MX360186B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198529 2012-12-20
PCT/EP2013/077300 WO2014096139A1 (en) 2012-12-20 2013-12-19 Solid oral dosage form of testosterone derivative

Publications (2)

Publication Number Publication Date
MX2015007436A true MX2015007436A (es) 2015-09-16
MX360186B MX360186B (es) 2018-10-24

Family

ID=47471565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007436A MX360186B (es) 2012-12-20 2013-12-19 Forma de dosificacion oral solida de derivado de testosterona.

Country Status (6)

Country Link
US (2) US20140179655A1 (es)
EP (1) EP2934591B1 (es)
CA (1) CA2931086C (es)
ES (1) ES2638981T3 (es)
MX (1) MX360186B (es)
WO (1) WO2014096139A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029271B1 (pt) * 2014-06-19 2023-04-04 Solural Pharma ApS Forma sólida de dosagem oral de compostos lipofílicos
KR102165548B1 (ko) * 2017-11-28 2020-10-14 (주)아이엠디팜 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
WO2022216769A1 (en) * 2021-04-07 2022-10-13 Fontana Biosciences, Inc. Rapidly disintegrating allyl isothiocyanate tablet

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098802A (en) 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
HUT71514A (en) 1992-05-21 1995-12-28 Endorecherche Inc Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU5486899A (en) 1998-08-13 2000-03-06 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
US6977083B1 (en) 1998-10-02 2005-12-20 Jenapharm Gmbh & Co. Kg Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2439873A1 (en) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly desintegrable tablet
AUPR573001A0 (en) 2001-06-15 2001-07-12 Glaxo Wellcome Australia Ltd Lymphatic drug delivery system
US20050287203A1 (en) 2002-05-08 2005-12-29 Nijs De H Formulation comprising testosteron undecanoate and castor oil
US20080305177A1 (en) 2002-11-14 2008-12-11 Alvin Kershman Method of administering testosterone
JP2006508967A (ja) 2002-11-14 2006-03-16 シャー／カーシュマン ラボラトリーズ インコーポレイテッド 改善された持続放出性を有する経口テストステロン供与システム
US20050100608A1 (en) 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US7138389B2 (en) 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
HUE061300T2 (hu) 2005-04-15 2023-06-28 Clarus Therapeutics Inc Gyógyszer szállítórendszerek hidrofób gyógyszerekhez és az azokat tartalmazó készítmények
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20110160168A1 (en) * 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
ES2525520T3 (es) 2010-04-12 2014-12-26 Clarus Therapeutics, Inc. Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions

Also Published As

Publication number Publication date
US9682148B2 (en) 2017-06-20
MX360186B (es) 2018-10-24
EP2934591B1 (en) 2017-08-09
CA2931086A1 (en) 2014-06-26
ES2638981T3 (es) 2017-10-24
EP2934591A1 (en) 2015-10-28
US20150328233A1 (en) 2015-11-19
CA2931086C (en) 2020-11-03
US20140179655A1 (en) 2014-06-26
WO2014096139A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2016016173A (es) Forma de dosis oral solida de compuestos lipofilicos.
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
PH12014501656A1 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2014057362A3 (en) Omega -3 compositions
DOP2014000301A (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
HK1209361A1 (en) Compositions and methods for transmucosal absorption
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
HK1255729A1 (zh) 包含針對pcsk9的人抗體的藥物組合物
MX2015007436A (es) Forma de dosificacion oral solida de derivado de testosterona.
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
NZ702930A (en) Racecadotril liquid compositions
MX2020008031A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
GB2502032A (en) Vitamin D composition
SA515361092B1 (ar) تركيبات راسكادوتريل الدهنية
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
HK1210058A1 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
WO2013028904A3 (en) Dermal filler compositions including antioxidants
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
MX369778B (es) Potenciadores de solubilidad del agua a base de glucogeno.
WO2014031982A3 (en) Methods and compositions for treating pain
EP2750655A4 (en) ANTI-TRANSPIRATION COMPOSITIONS AND PRODUCTS HAVING IMPROVED MOISTURE PROTECTION AND METHODS OF MAKING THE SAME
EP2922816A4 (en) DIETHYL ESTERS OF DTPA, COMPOSITIONS THEREOF, AND METHODS OF USE
ZA201401941B (en) Compositions to be applied to the skin, and uses thereof
WO2011138762A3 (en) Cholesterol ester for reducing cholesterol absorption

Legal Events

Date Code Title Description
FG Grant or registration